By: Sam Kashani, MD, FAASM In August 2021, Jazz Pharmaceuticals announced the US FDA approval of Xywav for the treatment of idiopathic hypersomnia in adults. Xywav, an oral solution consisting primarily of oxybate (GHB), already has approval for the treatment of...

read more